Skip to content
Search

Latest Stories

Unprecedented financial pressure will cause irreparable damage to pharmacy: APPG report

A new inquiry launched to assess the impact of Covid-19 on English pharmacies has revealed that without urgent government action, financial pressure will cause irreparable damage to the sector.

The flash inquiry conducted by the All-Party Parliamentary Group on Pharmacy (APPG) found that while pharmacy teams have been responding to the pandemic in heroic fashion, the sector is being pushed to breaking point because of unprecedented operational and financial pressures.


The group of MPs and peers heard that more than nine in 10 members of the pharmacy workforce felt their place of work was under severe financial pressure with nearly half of pharmacy contractors warning that they could close within a year.

"The pandemic has amplified and accelerated the worrying trends in pharmacy,” a report published by the group stated on Monday (Dec 14).

The survey, which involved 1,604 pharmacy professionals, found that 80 per cent contractors felt government loans to the tune of f £370m as advanced payments were not been enough to mitigate their financial woes. This loan released in three three separate instalments has been the only support package offered by government to deal with pharmacy's ' pandemic costs, which has left many contractors deeply concerned about how they will pay this back in the future.

While 91 per cent respondents felt that the government did not appreciate the role of pharmacy in frontline healthcare, 80 per cent said they did not have access to any asymptomatic testing for Covid-19.

“The public rightly recognise pharmacy teams continue to lift heaven and earth to remain open and ensure the safe supply of medicines during the pandemic," chair of the APPG, Jackie Doyle-Price, said. "But people would be shocked to hear that unprecedented financial pressure is now pushing many pharmacies to close."

Urging the government to "seize on this opportunity to unleash the potential of pharmacy," she pointed out that the report "outlines both the amazing response and suggestions for how the government can support pharmacies."

The report has examples of how the potential value of properly investing in pharmacy and reform could save the NHS money and provide better outcomes for patients. "Evidence submitted to us was filled with examples of pharmacies providing a lifeline to communities, often directly saving lives. But it also conveyed a bleak outlook for the future highlighting the irreversible damage that is being caused to the pharmacy network."

The survey results also indicated a high degree of burn-out in the workforce with many pharmacy contractors feeling that they are regarded almost as a charity service having to survive with uncertain and insufficient cashflow.  "A flat funding structure and rising costs are forcing pharmacies to operate with financial problems no business can endure."

The report recommends:

  • Government should look back at the response from pharmacies during Covid and use this as a basis to revaluate a clear vision of what the country needs from pharmacy as vital frontline healthcare workers.
  • Government and NHS leaders should consult on and undertake action to empower pharmacists to do more by providing more resources for training and supercharge the workforce which has shown it is a vital component of the NHS. In particular, a focus on training more independent prescribers and, critically, commissioning services that enable them to put their skills to best use, would be helpful.
  • There needs to be a revaluation at both the heart of government and within finance teams in the Department of Health and Social Care and NHS England about the value of pharmacy
  • Government should write off the advanced payments as an immediate way of providing relief to the sector. The government should consider the financial implications of asking the sector to pay back the £370m advanced payments at a time where immediate pressures are pushing many community pharmacies to the brink and payments had not been enough to cover the financial pressures brought on by Covid-19
  • In order to preserve the future sustainability of pharmacies we urge government to consider boosting overall funding in recognition of both the great financial pressures faced and the huge contribution made to frontline healthcare during the pandemic. It is clear that current funding levels may already be causing irreparable damage to pharmacies and without some kind of reform the number of pharmacies in England could substantially decrease.

Alongside chair Jackie Doyle-Price MP, the All-Party Parliamentary Group on Pharmacy has Sir David Amess, Paul Bristow, Feryal Clark, Jason McCartney, Taiwo Owatemi, Julian Sturdy, Lord Clement Jones and Baroness Cumberlege serving as members.

A survey of the pharmacy workforce as well as a call for evidence was launched by the group on November 17 and ran until November 30.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less